Breaking News Instant updates and real-time market news.

AAPL

Apple

$155.98

-3.78 (-2.37%)

, MU

Micron

$41.31

-0.34 (-0.82%)

07:35
10/20/17
10/20
07:35
10/20/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Thursday in Apple (AAPL), Micron (MU), Teva (TEVA), Verizon (VZ), Union Pacific (UNP), Qualcomm (QCOM), Caesars (CZR), Anheuser Busch (BUD), Ulta Beauty (ULTA), and Ally Financial (ALLY).

AAPL

Apple

$155.98

-3.78 (-2.37%)

MU

Micron

$41.31

-0.34 (-0.82%)

TEVA

Teva

$14.93

0.31 (2.12%)

VZ

Verizon

$49.21

0.56 (1.15%)

UNP

Union Pacific

$112.01

1.63 (1.48%)

QCOM

Qualcomm

$52.29

0.08 (0.15%)

CZR

Caesars

$12.05

-0.25 (-2.03%)

BUD

AB InBev

$125.94

0.14 (0.11%)

ULTA

Ulta Beauty

$204.62

6.25 (3.15%)

ALLY

Ally Financial

$24.52

0.04 (0.16%)

  • 22

    Oct

  • 23

    Oct

  • 25

    Oct

  • 26

    Oct

  • 26

    Oct

  • 01

    Nov

  • 01

    Nov

  • 02

    Nov

  • 02

    Nov

  • 08

    Nov

AAPL Apple
$155.98

-3.78 (-2.37%)

10/16/17
10/16/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Apple (AAPL) was upgraded to Overweight from Sector Weight at KeyBanc and Pacific Crest. 2. Infinera (INFN) upgraded to Neutral from Sell at Citi with analyst Stanley Kovler saying the risk/reward is balanced with material downward revisions to estimates likely limited. 3. AstraZeneca (AZN) upgraded to Outperform from Neutral at Credit Suisse with analyst Rebekah Harper saying that after recent pipeline success for Tagrisso and Imfinzi, she sees a marked improvement in its strategic position in pricing power and replacement power. 4. KKR (KKR) upgraded to Buy from Neutral at Goldman Sachs with analyst Alexander Blostein citing a more stable, improving mix of balance sheet investments, lower concentration in large public holdings, and increased mix towards private holdings. 5. Groupon (GRPN) upgraded to Market Perform from Underperform at Cowen with analyst Thomas Champion saying he believes the shares currently look more attractive given the company's new management and cost controls, improved North America results, and balanced expectations for the second half of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/17
KEYB
10/16/17
UPGRADE
KEYB
Overweight
Apple upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Andy Hargreaves upgraded Apple to Overweight from Sector Weight with a price target of $187. The shares closed Friday up 99c to $156.99. Apple is in the early stages of a "more aggressive market segmentation strategy" that will likely increase its gross profit per user and drive gross margin higher, Hargreaves tells investors in a research note. The analyst, however, remains "somewhat pessimistic" on iPhone unit growth volumes. Increased gross margin assumptions rise his earnings per share estimate for fiscal year 2018 to $11.68 from $11.07. The analyst believes initial iPhone mix is likely to suggest strong high-end demand. This report updates the firm to KeyBanc, which previously merged with Pacific Crest.
10/16/17
KEYB
10/16/17
NO CHANGE
KEYB
Apple supply chain to remain range-bound, says KeyBanc
KeyBanc analyst John Vinh says that because of supply constraints associated with the iPhone X, he anticipates Apple (AAPL) supply chain stocks will likely remain range-bound in the near term, given constraints make upside to estimates less likely, and constraints make it hard to assess true demand for the iPhone X. Additionally, his latest carrier survey indicates relatively lean iPhone 8 inventories despite muted demand and slightly higher demand for the iPhone 7. The analyst recommends investors continue to own Broadcom (AVGO), Cirrus Logic (CRUS), and Skyworks (SWKS).
10/19/17
DRXL
10/19/17
NO CHANGE
Target $208
DRXL
Buy
Drexel Hamilton 'aggressive buyers' of Apple on order cut report weakness
Drexel Hamilton analyst Brian White said he would be an "aggressive buyer" of Apple shares amid the weakness that he attributes to media reports around order cuts for the iPhone 8/8 Plus. He believes the staggered launch of the iPhone 8/8 Plus and iPhone X is causing more confusing data points relative to past cycles and notes that Apple has cut forecasts before "even during some of the best iPhone cycles." The analyst, who notes that consumers are waiting on the iPhone X, keeps a Buy rating and $208 price target on Apple shares, which are down 2.4% to $155.92 in early trading.
MU Micron
$41.31

-0.34 (-0.82%)

10/16/17
NOMU
10/16/17
NO CHANGE
Target $50
NOMU
Buy
Nomura boosts Micron target to $50, calls dilution concerns 'overblown'
In a research note titled "MU Sold Shares, But You Shouldn't," Nomura Instinet analyst Romit Shah raised his price target shares of Micron Technology to $50 from $45 and keeps a Buy rating on the name. The chipmaker closed Friday down 18c to $40.40. The analyst puts investor sentiment following last week's $1.2B secondary somewhere between "healthy skepticism and mild distrust." He believes dilution concerns are "overblown," however. Management's guidance to reduce net debt to zero in fiscal year was an important announcement, Shah argues.
10/12/17
LEHM
10/12/17
NO CHANGE
Target $60
LEHM
Overweight
Micron price target raised to $60 from $40 at Barclays
Barclays analyst Blayne Curtis raised his price target for Micron Technology shares to $60 from $40 says memory trends look good into next year. The pricing environment for DRAM "continues to improve at a strong pace," Curtis tells investors in a research note where he raised his estimates for Micron. NAND is also accelerating before smartphone ramps in the second half of 2017 and should remain supply constrained into the second half of 2018 as data center customers continue to have "insatiable demand" for flash, the analyst adds. He reiterates an Overweight rating on the shares. Micron closed yesterday down 37c to $41.61.
10/19/17
UBSW
10/19/17
NO CHANGE
Target $53
UBSW
Buy
Micron price target raised to $53 from $39.50 at UBS
UBS analyst Stephen Chin raised his price target on Micron to $53 from $39.50 as near-term demand and memory pricing trends appear to be performing in-line to slightly ahead of expectations and valuation remains attractive. The analyst said DRAM is still the biggest driver of profits and supply remains in check. Chin reiterated his Buy rating on Micron shares.
10/11/17
NOMU
10/11/17
NO CHANGE
Target $45
NOMU
Buy
Micron unlocking value in 'unconventional way,' says Nomura Instinet
Nomura Instinet analyst Romit Shah believes Micron's $1B secondary offering is management is being "financially shrewd and unlocking shareholder value in an unconventional way." Micron is using its stock currency following the appreciation over the past year to deleverage its balance sheet, Shah tells investors in a research note titled "Deleveraging While the Getting Is Good." The move should accelerate the company's target of achieving an interim debt target of $8B-9B in fiscal year of 2018, versus $11.1B currently, the analyst adds. He believes the dilution will be minimal at around 15c. Shah keeps a Buy rating on Micron with a $45 price target.
TEVA Teva
$14.93

0.31 (2.12%)

10/13/17
WELS
10/13/17
NO CHANGE
Target $276
WELS
Outperform
Allergan settlement leaves three Restasis challengers, say Wells Fargo
Wells Fargo analyst David Maris says three Restasis generic challengers remain after Allergan (AGN) reached a settlement with InnoPharma. The settlement, which allows InnoPharma to launch a generic Restasis in the U.S. beginning February 24, 2024, or six months before the expiration of Allergan's patents, points to the complexity of Restasis and the difficulty of getting a generic version approved, Maris tells investors in a research note. InnoPharma was one of four included in a consolidated lawsuit against Allergan, with Teva (TEVA), Mylan (MYL) and Akorn (AKRX) remaining, Maris points out. He's encouraged that the settlement date reached with InnoPharma is close to the expiration date of the patents. The analyst keeps an Outperform rating on Allergan with a $276 price target.
10/04/17
JPMS
10/04/17
NO CHANGE
JPMS
Overweight
JPMorgan says generic Copaxone approval 'meaninful positive' for Mylan
Mylan's (MYL) generic Copaxone approval, 9-12 months ahead of investor expectations, represents a "meaningful positive" for the story and will "substantially derisk/support" upside to 2017 and 2018 estimates, JPMorgan analyst Chris Schott tells investors in a research note. The analyst reiterates an Overweight rating on the shares. For Teva (TEVA), the approval puts further pressure on the company's "already challenged" near-term earnings profile and delevering efforts, Schott writes. The analyst keeps a Neutral rating on the shares. The analyst believes the earlier than expected approval for Mylan represents a setback for Momenta Pharmaceuticals' (MNTA) generic Copaxone opportunity. Schott had assumed the company's Glatopa would be the first generic version of Copaxone 40mg to enter the market, but he notes the product has been delayed due to manufacturing issues at a Pfizer (PFE) plant handling fill/ for the drug. The analyst, however, continues to see a "large and fairly durable" generic opportunity for Glatopa. He keeps an Overweight rating on Momenta shares, which are down 27% in premarket trading to $12.75. Mylan is up 17% to $38.20 while Teva is down 15% to $15.95.
10/04/17
BTIG
10/04/17
NO CHANGE
BTIG
Mylan generic Copaxone sales could reach $450M in first year, says BTIG
BTIG analyst Timothy Chiang estimates that Mylan (MYL) could obtain up to $450M of sales from its generic version of Teva's (TEVA) Copaxone in the first year in which it is marketed. The analyst believes that the approval "validates" the company's status as a "premier" generic drugmaker and shows that one can never assume that it will lose a battle over generic drug rights. The analyst raised his price target on the shares to $45 from $42 and keeps a Buy rating on the stock.
10/16/17
WELS
10/16/17
NO CHANGE
WELS
Outperform
Court ruling looks 'clearly negative' for Allergan, says Wells Fargo
Wells Fargo analyst David Maris says a federal judge ruling today that Allergan's (AGN) Restasis patents are invalid "appears clearly negative" for the company. Due to the magnitude of the potential damages involved, however, an at-risk generic launch is unlikely, Maris tells investors in an intraday research note. As such, the analyst continues to believe the earliest that a generic version of Restasis may enter the market is sometime in 2019. Maris keeps an Outperform rating on Allergan. He adds that today's court ruling is incrementally positive for generic Restasis filers, if approved, including Teva (TEVA), Mylan ( MYL) and Akorn (AKRN).
VZ Verizon
$49.21

0.56 (1.15%)

09/20/17
OPCO
09/20/17
NO CHANGE
OPCO
Perform
Oppenheimer expects Sprint, T-Mobile merger to happen
Oppenheimer analyst Timothy Horan expect T-Mobile (TMUS) to merge with Sprint (S) in a stock-for-stock transaction at a $10 per share Sprint valuation. A T-Mobile/Sprint will be a better competitor to Verizon (VZ)/AT&T (T), the analyst says, adding that while the process is likely to have a few bumps and require time, he expects a merger to happen. Horan reiterates a Perform rating on Sprint's shares.
10/19/17
SBSH
10/19/17
NO CHANGE
Target $55
SBSH
Buy
Verizon shares to move up near-term on Q3 results, says Citi
Citi analyst Michael Rollins views this morning's Q3 results from Verizon Communications as positive citing the postpaid phone gains and recovering wireless service revenue. The quarter affirms the company's opportunity to improve the trajectory of wireless service revenue over the next 12 months while generating solid cash flow, Rollins tells investors in a post-earnings research note. The analyst expects Verizon shares to trade higher near-term on the back of these results. He keeps a Buy rating on the name with a $55 price target. Rollins notes Verizon's capex of $4.3B was just below his $4.4B forecast. Capex is now expected to be $16.8B, below the analyst's estimate of $17.0B.
10/16/17
10/16/17
DOWNGRADE

Perform
Crown Castle downgraded to Perform at Oppenheimer
As previously reported, Oppenheimer analyst Timothy Horan downgraded Crown Castle (CCI) to Perform from Outperform saying that recent reports denote a T-Mobile (TMUS)/Sprint (S) merger is imminent, and as it represents 40% of revenues and will be aggressively slashing supplier spending, which will offset growth in 600 MHz, FirstNet, 5G. The analyst sees a 70% probability of the deal receiving approval with major concessions and likely also attacking the wireline market and better able to compete with Verizon (VZ)/AT&T (T) on coverage/capacity.
09/20/17
DBAB
09/20/17
NO CHANGE
DBAB
Sprint, T-Mobile merger unlikely to get regulatory approval, says Deutsche Bank
Deutsche Bank analyst Matthew Niknam continues to believe a potential merger between Sprint (S) and T-Mobile (TMUS) faces "significant hurdles" and is ultimately unlikely to get past regulatory concerns. Merits of the deal, however, are "unparalleled, and very tough to debate," Niknam tells investors in a research note following CNBC's report of progressing deal talks. He believes derivative stock reactions on the news, namely strength in AT&T (T) and Verizon (VZ) and weakness in the tower names, could be at risk of reversing. Among the towers, the analyst has Buy ratings on American Tower (AMT) and Crown Castle (CCI).
UNP Union Pacific
$112.01

1.63 (1.48%)

10/10/17
AGIS
10/10/17
DOWNGRADE
Target $122
AGIS
Hold
Union Pacific downgraded to Hold from Buy at Aegis
Aegis analyst Jeffrey Kauffman downgraded Union Pacific to Hold from Buy citing valuation, noting that its outlook deteriorates about 2% in both 2017 and 2018 in his view given that volumes have been more challenged in the coal and automotive markets and grain comparisons get tougher. However, given higher market valuations, he has raised his price target on the stock to $122 from $120.
10/04/17
SBSH
10/04/17
DOWNGRADE
SBSH
Neutral
Union Pacific downgraded to Neutral from Buy at Citi
Citi analyst Christian Wetherbee downgraded Union Pacific (UNP) to Neutral saying the Q3 rally in rail stocks has "pulled forward value." It is getting more challenging to see enough upside to broadly recommend names, Wetherbee tells investors in a research note. The analyst remains focused on Kansas City Southern (KSU) as his top pick. He keeps a $120 price target for shares of Union Pacific.
10/02/17
MSCO
10/02/17
DOWNGRADE
Target $100
MSCO
Equal Weight
Union Pacific downgraded on weaker auto, coal volumes at Morgan Stanley
As previously reported, Morgan Stanley analyst Ravi Shanker downgraded Union Pacific (UNP) to Equal Weight from Overweight, saying he believes it will likely "bear the brunt" of weaker auto and coal volumes into 2018. The analyst, who also downgraded CSX (CSX) to Underweight from Equal Weight this morning, said he believes volume growth will be incrementally harder for the rail sector in the second half and into 2018. Shanker cut his price target on Union Pacific to $100 from $102.
10/02/17
MSCO
10/02/17
DOWNGRADE
MSCO
Equal Weight
Union Pacific downgraded to Equal Weight from Overweight at Morgan Stanley
QCOM Qualcomm
$52.29

0.08 (0.15%)

09/15/17
09/15/17
UPGRADE
Target $62.5

Outperform
Qualcomm upgraded to Outperform on 3D sensing opportunity at Northland
As previously reported, Northland analyst Tom Sepenzis upgraded Qualcomm (QCOM) to Outperform from Market Perform on expectations for market share gains in 2018, particularly at the high end, as he sees the company and partner Himax (HIMX) as well positioned to become the "de facto leading 3D sensing solution" with Android manufacturers who follow the lead of Apple's (AAPL) new iPhone X. From what he understands, handset makers that want to use its SLiM structured light solution will have to use Qualcomm's next generation Snapdragon chipset too, he tells investors. Sepenzis keeps a $62.50 price target on Qualcomm shares.
09/22/17
RBCM
09/22/17
NO CHANGE
Target $9.5
RBCM
Sector Perform
BlackBerry can use $1.6B of cash on acquisitions, says RBC Capital
RBC Capital analyst Paul Treiber says BlackBerry (BBRY) has $2.36B in cash after the $940M award from Qualcomm (QCOM). The company can use up to $1.6B of the cash on acquisitions, which may be accretive to earnings and the stock price, Treiber tells investors in a research note. He fells an acquisition of a company with organic growth above BlackBerry's targeted 10%-15% software growth "would be a tailwind to BlackBerry's organic growth." Treiber expects in-line Q2 results from BlackBerry on September 28 and keeps a Sector Perform rating on the shares.
09/15/17
NORL
09/15/17
UPGRADE
NORL
Outperform
Qualcomm upgraded to Outperform from Market Perform at Northland
09/15/17
09/15/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Dish (DISH) upgraded to Neutral from Sell at Citi with analyst Jason Bazinet saying the valuation seems fair following the recent weakness in the shares. 2. First Solar (FSLR) upgraded to Buy from Hold at Deutsche Bank with analyst Vishal Shah saying channel checks indicate that "robust" U.S. demand is driving module prices higher. 3. Southwest (LUV) upgraded to Overweight from Neutral at JPMorgan with analyst Jamie Baker saying the recent correction in Southwest shares makes for a "compelling" risk-to-reward profile. 4. Qualcomm (QCOM) upgraded to Outperform from Market Perform at Northland with analyst Tom Sepenzis citing expectations for market share gains in 2018, particularly at the high end, as he sees the company and partner Himax (HIMX) as well positioned to become the "de facto leading 3D sensing solution" with Android manufacturers who follow the lead of Apple's (AAPL) new iPhone X. 5. Harsco (HSC) upgraded to Buy from Hold at Argus with analyst David Coleman saying cost cutting initiatives, returns on prior investments, and improving end market demand have resulted in above Street results in the first half of 2017. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CZR Caesars
$12.05

-0.25 (-2.03%)

10/06/17
10/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. GoDaddy (GDDY) initiated with an Outperform at William Blair. 2. Green Dot (GDOT) initiated with a Buy at Craig-Hallum. 3. Abbott (ABT) reinstated with a Neutral at JPMorgan. 4. Caesars (CZR) initiated with a Neutral at Nomura Instinet. 5. Tech Data (TECD) initiated with a Buy at Pivotal Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/06/17
NOMU
10/06/17
INITIATION
Target $14
NOMU
Neutral
Caesars initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst Brian Dobson started Caesars Entertainment with a Neutral rating and $14 price target. The analyst believes the company's growth catalysts are largely discounted in the shares.
07/21/17
WOLF
07/21/17
INITIATION
Target $16
WOLF
Outperform
Caesars initiated with an Outperform at Wolfe Research
Wolfe initiated Caesars with an Outperform and a $16 price target.
09/15/17
RHCO
09/15/17
INITIATION
Target $14
RHCO
Buy
Caesars initiated with a Buy at SunTrust
SunTrust analyst Patrick Scholes initiated Caesars with a Buy and a $14 price target given his positive view on regional gaming and Vegas strip fundamentals: Scholes believes US gaming is a consolidating industry and Caesars could emerge as a leading consolidator and also purse sale-leaseback opportunities.
BUD AB InBev
$125.94

0.14 (0.11%)

09/08/17
ARGS
09/08/17
INITIATION
ARGS
Buy
AB InBev initiated with a Buy at Argus
Argus analyst Stephen Biggar started coverage of AB InBev with a $136 price target and a Buy rating. The analyst noted that the company's organic growth accelerated year-over-year in 1H17. He thinks that the company's growth can accelerate modestly going forward, while its margins can rise. The analyst says that the company can benefit from increased penetration in emerging markets, higher demand for premium beers and increased sales of nonalcoholic drinks.
05/05/17
STFL
05/05/17
NO CHANGE
STFL
AB InBev price target raised to $134 from $116 at Stifel
Stifel analyst Mark Swartzberg increased his price target on AB InBev, citing the company's improved organic growth and its recent trend of ramping up the distribution of beverages it acquired in multiple markets. He expects the company's accelerated growth rate to continue and keeps a Buy rating on the shares.
09/08/17
09/08/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DowDuPont (DWDP) initiated with a Top Pick at RBC Capital. 2. Electronic Arts (EA) was initiated with a Conviction Buy while Activision Blizzard (ATVI) was initiated with a Neutral at Goldman Sachs. 3. AB InBev (BUD) initiated with a Buy at Argus. 4. LivaNova (LIVN) initiated with a Buy at Jefferies. 5. Fate Therapeutics (FATE) resumed with an Outperform at Leerink. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/17
SUSQ
10/02/17
NO CHANGE
Target $135
SUSQ
Positive
PepsiCo could be next takeout for AB In Bev, says Susquehanna
Susquehanna analyst Pablo Zuanic noted Pepsico (PEP) reports Q3 on October 3rd and he projects year-to-date metrics and earnings are below consensus. He trimmed his North American sales growth on weaker trends than expected, but he believes the potential miss could already be reflected in the shares. The analyst said based on valuation and fundamentals the stock deserves a Neutral rating but he continues to see it as the next logical target for AB InBev (BUD) in a joint bid with Kraft Heinz (KHC). Zuanic keeps a $135 price target on PepsiCo shares.
ULTA Ulta Beauty
$204.62

6.25 (3.15%)

10/19/17
DADA
10/19/17
NO CHANGE
DADA
DA Davidson speculates on whether Amazon should buy Sally Beauty
With Sally Beauty (SBH) shares trading lower intraday, DA Davidson analyst Linda Bolton Weiser published a note in which she covered seven points to consider when evaluating whether the company will be, or should be, an acquisition target for Amazon (AMZN). The analyst, who also attributed today's strength in Ulta Beauty (ULTA) to speculation that Wal-Mart (WMT) will buy it, said beauty has been a hard category to crack for Amazon. She concludes that Sally Beauty's "uniquely high gross margin of 55% and high number of U.S. retail stores" were key reasons why Amazon has chosen the company as its beauty partner.
10/18/17
PIPR
10/18/17
NO CHANGE
Target $26
PIPR
Overweight
e.l.f. Beauty price target lowered to $26 from $32 at Piper Jaffray
Piper Jaffray analyst Erinn Murphy lowered her price target for e.l.f. Beauty (ELF) to $26 after her firm's Fall teen survey indicated category spending dynamics are slowing with color cosmetics spending down 13% year-over-year. Murphy this morning also downgraded shares of Ulta Beauty (ULTA) to Neutral. The survey findings are a net positive for e.l.f., however, as the company made its debut as a top-10 cosmetics brands for upper-income teens in the number eight spot, the analyst tells investors in a research note. She keeps an Overweight rating on the name.
10/18/17
10/18/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Chevron (CVX) was downgraded to Hold from Buy at Societe Generale and to Market Perform on valuation at BMO Capital. 2. Ulta Beauty (ULTA) downgraded to Neutral from Overweight at Piper Jaffray with analyst Erinn Murphy saying her firm's Fall teen survey indicated spending declines in color cosmetics among all female teens. 3. Chipotle (CMG) downgraded to Underperform from Neutral at BofA/Merrill with analyst Gregory Francort saying he believes Chipotle has down a "very good job" managing labor costs but expects further gains to be difficult, combined with the tough sales backdrop, will limit further margin expansion. 4. Roche (RHHBY) downgraded to Neutral from Buy at Citi with analyst Andrew Baum saying Roche's rate of progress in the immuno-oncology field have underperformed. 5. Blackhawk (HAWK) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/18/17
PIPR
10/18/17
DOWNGRADE
Target $210
PIPR
Neutral
Ulta Beauty downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Erinn Murphy downgraded Ulta Beauty to Neutral and cut her price target for the shares to $210 from $260. The analyst says her firm's Fall teen survey indicated spending declines in color cosmetics among all female teens. Skincare declines were less bad, but taken together with trough fragrance spending, overall beauty wallet contracted low-double digits, Murphy tells investors in a research note. She notes the survey findings leave her "incrementally concerned on current category dynamics."
ALLY Ally Financial
$24.52

0.04 (0.16%)

08/31/17
JANY
08/31/17
NO CHANGE
JANY
Janney says Harvey impact could help used car pricing, credit performance
Janney Capital analyst John Rowan noted that Cox Automotive estimates that up to half a million cars will be scrapped as a results of Hurricane Harvey, which could go a long way toward removing the increased wholesale supply of used vehicles and could lead to better pricing later in the year. If prices do firm up, credit performance should also improve, said the analyst, who "would venture to make an educated guess" that non-bank financials that cater to lower credit score consumers are at a "disproportionate advantage" in such a scenario. Companies that specialize in subprime automotive financing include Ally Financial (ALLY), America's Car-Mart (CRMT), OneMain Holdings (OMF) and Santander Consumer (SC).
07/17/17
SPHN
07/17/17
DOWNGRADE
SPHN
Underweight
Ally Financial downgraded to Underweight from Equal Weight at Stephens
06/09/17
PIPR
06/09/17
INITIATION
Target $25
PIPR
Overweight
Ally Financial initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Kevin Barker started Ally Financial with an Overweight rating and $25 price target. The analyst views the stock's risk/reward as one of the best within financials. The analyst sees a four-to-one upside/downside scenario for patient investors willing to wait for a slightly more favorable environment.
10/17/17
SBSH
10/17/17
INITIATION
Target $30
SBSH
Buy
Ally Financial initiated with a Buy at Citi
Citi analyst Arren Cyganovich started Ally Financial with a Buy rating and $30 price target. The analyst sees the company continuing to execute on its medium-term growth plan to expand net finance margin by lowering its funding costs, raising its portfolio yield, and diversifying its business as a leading digital bank.

TODAY'S FREE FLY STORIES

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 06

    Dec

WGL

WGL Holdings

$84.32

-0.14 (-0.17%)

18:01
11/17/17
11/17
18:01
11/17/17
18:01
Earnings
WGL Holdings reports Q4 adjusted EPS (17c), consensus (19c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

, LMOS

Lumos Networks

17:58
11/17/17
11/17
17:58
11/17/17
17:58
Hot Stocks
Tactile Systems to replace Lumos Networks in S&P 600 at open on 11/22 »

EQT Infrastructure…

TCMD

Tactile Systems

$25.98

-0.23 (-0.88%)

LMOS

Lumos Networks

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

, MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

17:56
11/17/17
11/17
17:56
11/17/17
17:56
Hot Stocks
Breaking Hot Stocks news story on Invesco Mortgage, MKS Instruments »

Invesco Mortgage to…

IVR

Invesco Mortgage

$17.36

0.07 (0.40%)

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

, BRCD

Brocade

17:55
11/17/17
11/17
17:55
11/17/17
17:55
Hot Stocks
MKS Instruments to replace Brocade in S&P 400 at open on 11/22 »

S&P 500 constituent…

MKSI

MKS Instruments

$103.50

-0.35 (-0.34%)

BRCD

Brocade

AVGO

Broadcom

$271.86

-0.25 (-0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

UQM

UQM Technologies

$1.18

0.015 (1.29%)

17:24
11/17/17
11/17
17:24
11/17/17
17:24
Syndicate
Breaking Syndicate news story on UQM Technologies »

UQM Technologies files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$238.02

-1.35 (-0.56%)

17:23
11/17/17
11/17
17:23
11/17/17
17:23
Periodicals
Goldman Sachs has $510M lawsuit dismissed, Reuters reports »

A $510M lawsuit that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VICL

Vical

$1.94

-0.02 (-1.02%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Breaking Hot Stocks news story on Vical »

Biotechnology Value Fund…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:18
11/17/17
11/17
17:18
11/17/17
17:18
Hot Stocks
Ligand director sells 5,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CFO sells 6,559 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGND

Ligand

$140.31

-1.4 (-0.99%)

17:17
11/17/17
11/17
17:17
11/17/17
17:17
Hot Stocks
Ligand CEO sells 5,269 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MBI

MBIA

$9.01

0.13 (1.46%)

17:15
11/17/17
11/17
17:15
11/17/17
17:15
Hot Stocks
Breaking Hot Stocks news story on MBIA »

Fine Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RBCN

Rubicon

$8.07

0.1218 (1.53%)

17:03
11/17/17
11/17
17:03
11/17/17
17:03
Hot Stocks
Breaking Hot Stocks news story on Rubicon »

Bandera Partners reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ANCB

Anchor Bancorp

$24.75

-0.1 (-0.40%)

17:02
11/17/17
11/17
17:02
11/17/17
17:02
Hot Stocks
Anchor Bancorp announces stock repurchase program, 10b5-1 trading plan »

Anchor Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:58
11/17/17
11/17
16:58
11/17/17
16:58
Syndicate
Breaking Syndicate news story on Gulf Island Fabrication »

Gulf Island Fabrication…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MPB

Mid Penn Bancorp

$31.09

0.59 (1.93%)

16:51
11/17/17
11/17
16:51
11/17/17
16:51
Hot Stocks
Mid Penn Bancorp, Scottdale shareholders approve merger »

Mid Penn Bancorp and The…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALD

Callidus Software

$28.95

0.3 (1.05%)

16:49
11/17/17
11/17
16:49
11/17/17
16:49
Initiation
Callidus Software initiated at First Analysis »

Callidus Software…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GIFI

Gulf Island Fabrication

$12.30

-0.1 (-0.81%)

16:46
11/17/17
11/17
16:46
11/17/17
16:46
Hot Stocks
Breaking Hot Stocks news story on Gulf Island Fabrication »

Piton Capital Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$18.21

-0.04 (-0.22%)

16:42
11/17/17
11/17
16:42
11/17/17
16:42
Hot Stocks
General Electric CEO acquires 60,000 common shares »

In a regulatory filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRE

Northstar Realty Europe

$14.20

0.05 (0.35%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Syndicate
Breaking Syndicate news story on Northstar Realty Europe »

Northstar Realty Europe…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 29

    Nov

  • 30

    Nov

FHN

First Horizon

$18.40

0.1 (0.55%)

, CBF

Capital Bank

$39.95

0.25 (0.63%)

16:33
11/17/17
11/17
16:33
11/17/17
16:33
Hot Stocks
First Horizon, Capital Bank agree to sell two branches to Apex Bank »

First Horizon (FHN) and…

FHN

First Horizon

$18.40

0.1 (0.55%)

CBF

Capital Bank

$39.95

0.25 (0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$194.25

-0.75 (-0.38%)

16:32
11/17/17
11/17
16:32
11/17/17
16:32
Hot Stocks
Lennox executive sells 2,500 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

TBNK

Territorial Bancorp

$30.99

0.21 (0.68%)

16:31
11/17/17
11/17
16:31
11/17/17
16:31
Hot Stocks
Territorial Bancorp declares special cash dividend of 30c per share »

Payable on December 20.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRTN

Triton International

$40.07

-0.77 (-1.89%)

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Hot Stocks
Triton International's Hanau sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
11/17/17
11/17
16:30
11/17/17
16:30
Options
Preliminary option volume of 21.1M today »

Preliminary option volume…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.